MolMed news - the latest biotech news from Labiotech.eu

Home MolMed

Latest Posts

Cell and Gene Therapies Europe

Interview 18 Apr 2018

What Lies Ahead for European Cell and Gene Therapies?

Cell and gene therapies have recently made big advances in providing effective treatments for a variety of conditions, from cancers to rare diseases. Nonetheless, there are still significant challenges ahead before the technologies can become a viable treatment option for most patients. What if you could treat a disease on the level of tissue and […]

April 18, 2018 - 5 minutesmins - By Alexander Burik

biotech dinosaurs cover2 1

In Depth 23 Jan 2018

Walking with the Dinosaurs of European Biotech: Which of Them is Roaring the Loudest?

Although biotech may seem like an industry that has only just gotten started, it was already up and running before the turn of the century. We took a look back at the pre-2000 companies to see how they’re faring. According to our biotech map, there were 219 biotechs in Europe in 1999. Today, our map […]

January 23, 2018 - 10 minutesmins - By Alex Dale

MolMed ITW Cover2 1

Interview 4 Dec 2017

Meet the CEO Leading Italy’s Charge to Become a Major Biotech Player

Riccardo Palmisano is CEO of MolMed, the most important Italian biotech, which focuses on gene and cell therapies. We chatted about the company, which hopes to give the cancer therapies field a boost. You may have come across MolMed before, possibly in our recent piece on the top biotechs in Milan. The company was founded […]

December 4, 2017 - 7 minutesmins - By Alex Dale

chromosome koya979 FI

News and Trends 19 Sep 2016

Italian Gene Therapy Biotech aims high by Collaborating with US Giant Amgen

Genenta Science and Amgen have teamed up to develop gene therapies for cancer. The Italian biotech from Milan raised €10M in series A funding last year and is already getting ready for clinical trials. Genenta is developing a gene therapy platform for haematopoietic stem cells and wants to bring it to the clinic. Together with the San Raffaele Hospital and Scientific […]

September 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

molmed graft host disease zalmoxis leukemia

News and Trends 28 Jun 2016

Will the Leading Italian Biotech soon have its First Cell therapy on the Market?

MolMed has received conditional market approval for Zalmoxis, an ex vivo genetically engineered cell therapy that stops immune rejection of transplanted hematopoietic stem cells. This is a big step forward in a key treatment for blood cancers. A transplant of hematopoietic stem cells (cells that give origin to blood cells) is often used as part of treatments for […]

June 28, 2016 - 2 minutesmins - By Denise Neves Gameiro

molmed biotech of the week header

News and Trends 1 Apr 2016

Biotech of the Week: MolMed, Immuno-oncology made in ‘Milano’

From one fashion capital to the other, this week we leave Paris and head down to Milan. Home to some worldwide high-fashion brands, Da Vinci’s Last Supper mural and main city of the Lombardy region, Milan is also where MolMed, our Biotech of the Week, is based. City: Milan (Italy) Founded: 1996 Employees: (+/-) 120 (as of 12/2015) […]

April 1, 2016 - 1 minutemin - By Joachim Eeckhout

ADVERTISEMENT